Statute Details
- Title: Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016
- Act Code: MA1975-S336-2016
- Legislation Type: Subsidiary legislation (SL)
- Enacting Act / Authorising Powers: Medicines Act (Cap. 176), sections 18, 34, 44 and 74
- Commencement: 1 November 2016
- Status: Current version as at 27 Mar 2026 (with amendments reflected up to that date)
- Key Parts: Part 1 (General); Part 2 (Exemptions); Part 3 (Manufacture/Import); Part 4 (Supply); Part 5 (Duties/Records/Reports); Part 6 (Miscellaneous)
- Key Definitions (Section 2): “clinical research”, “clinical research material”, “investigational CRM”, “auxiliary CRM”, “protocol”, “sponsor”, “subject”, “regulated clinical trial”, and references to Healthcare Services Act 2020 concepts
- Key Operational Provisions: Sections 3–14; First Schedule (excluded medicinal products); Second Schedule (labelling requirements)
- Notable Amendments (from the timeline provided): S 439/2023 (effective 26/06/2023 and 31/12/2021); S 806/2023 (effective 18/12/2023)
What Is This Legislation About?
The Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016 (“CRM Regulations”) create a specialised regulatory framework for medicinal products that are used in human clinical research. In plain terms, the Regulations recognise that medicines used in research—whether as investigational products, placebos, or reference materials—often need to be handled differently from medicines supplied for routine clinical use. The Regulations therefore carve out exemptions from parts of the Medicines Act, while imposing targeted obligations on manufacture, import, supply, labelling, record-keeping, adverse event notification, and recall.
The scope is centred on “clinical research materials” (CRMs). A CRM is defined as a medicinal product or placebo (subject to exclusions in the First Schedule) that is manufactured, assembled, imported, or supplied for the purpose of being used in clinical research by administration to a research subject in accordance with the research protocol. This definition is crucial: it ties the regulatory treatment to both the nature of the product (medicinal product or placebo) and the purpose and manner of use (administration under a protocol in clinical research).
Although the Regulations are made under the Medicines Act, they interact with the broader clinical research ecosystem in Singapore, including the Human Biomedical Research Act 2015 and the Healthcare Services Act 2020. The CRM Regulations also align with the concept of “regulated clinical trials” under clinical trial regulations, and they use definitions that incorporate terminology from the Healthcare Services Act 2020 (such as “approved permanent premises” and “healthcare service licensee”).
What Are the Key Provisions?
1. Definitions and the regulatory “trigger” (Section 2). The Regulations begin by defining the terms that determine when the CRM regime applies. The most important definitional elements are: (i) what counts as “clinical research” (research involving human beings, whether or not it is a regulated clinical trial); (ii) what counts as “clinical research material” (medicinal product or placebo not in the First Schedule, manufactured/assembled/imported/supplied for use in clinical research under a protocol); and (iii) the distinction between “investigational CRM” (to be tested or used as a reference) and “auxiliary CRM” (used for the needs of the research but not as the material to be tested or used as a reference). These distinctions matter because obligations may vary depending on the role of the CRM in the research.
2. Exemptions from the Medicines Act for clinical research materials (Section 3). Part 2 provides exemptions from the Medicines Act. Practically, this means that certain regulatory requirements that would ordinarily apply to medicinal products supplied in the market may not apply in the same way when the product is being used as a CRM under a protocol. However, the exemptions are not a “free pass”: the Regulations replace general market-focused controls with research-focused controls—especially around manufacture/import/supply, labelling, records, and safety reporting.
3. Manufacture, assembly and import controls (Section 4). Part 3 addresses how CRMs may be manufactured, assembled, and imported. While the extract provided does not reproduce the full text of Section 4, the structure indicates that the Regulations impose conditions on these activities, typically requiring that CRMs be produced or handled in an appropriate manner and in compliance with the Regulations’ requirements. For practitioners, the key compliance question is whether the activity is within the CRM definition and whether the facility and process meet the regulatory conditions (including any references to “approved permanent premises” and “approved conveyance” concepts imported from the Healthcare Services Act 2020).
4. Supply restrictions and labelling (Sections 5 and 6; Second Schedule). Part 4 governs supply. Section 5 restricts supply so that CRMs are supplied only as clinical research materials—meaning the supply must be tied to the clinical research purpose and protocol use. Section 6 then requires that CRMs be supplied with proper labelling. The Second Schedule sets out labelling requirements, which are central to safe administration in research settings. For legal and compliance teams, labelling is often where audit findings arise: the labelling must support traceability, correct identification of the product and its role in the trial (e.g., investigational vs placebo/reference), and it must satisfy the prescribed content and format requirements.
5. Duties relating to CRMs: dealing, records, and safety reporting (Sections 7–13). Part 5 is the operational heart of the Regulations. Division 1 (Section 7) addresses “dealing” with CRMs, which typically covers handling, storage, transfer, and other forms of management during the research lifecycle. Division 2 (Sections 8–11) imposes record-keeping obligations. These include records of manufacture (Section 8), records of receipt and supply (Section 9), and records of dealings with CRMs (Section 10). Section 11 then specifies the production of and time for keeping records. For practitioners, this means that compliance is not only about having records but also about maintaining them for the required duration and making them available as required by the regulatory scheme.
Division 3 (Sections 12 and 13) imposes reporting duties to the Authority. Section 12 requires notifications of unexpected serious adverse drug reactions. This is a safety-critical obligation: it requires prompt notification when serious adverse reactions occur that are unexpected in the context of the research. Section 13 provides for recall of clinical research material. A recall mechanism is essential where a CRM may pose risks due to quality, labelling, or other safety concerns. Together, these provisions ensure that CRMs remain subject to pharmacovigilance and risk management principles, even where the Medicines Act is partially exempted.
6. Offences (Section 14). Part 6 contains offences. While the extract does not detail the offence wording, the presence of a dedicated offences section signals that breaches of the Regulations—such as improper supply, inadequate labelling, failure to keep required records, failure to notify unexpected serious adverse reactions, or failure to comply with recall—attract criminal or regulatory penalties under the subsidiary legislation framework.
How Is This Legislation Structured?
The CRM Regulations are organised into a clear compliance pathway:
Part 1 (General) sets out the citation and commencement (1 November 2016) and provides core definitions in Section 2. These definitions are foundational for determining whether a product and activity are within scope.
Part 2 (Exemptions for Clinical Research Materials) contains Section 3, which provides exemptions from the Medicines Act for CRMs, subject to the overall regulatory framework.
Part 3 (Manufacture, Assembly and Import of Clinical Research Materials) contains Section 4, establishing conditions for manufacturing, assembling, and importing CRMs.
Part 4 (Supplies, Etc., of Clinical Research Materials) contains Sections 5 and 6, focusing on supply limitations and labelling requirements (with detailed labelling rules in the Second Schedule).
Part 5 (Duties Relating to Clinical Research Materials) is divided into three functional divisions: (i) dealing with CRMs (Section 7); (ii) record-keeping (Sections 8–11); and (iii) reports to the Authority, including adverse reaction notifications and recall (Sections 12–13).
Part 6 (Miscellaneous) contains Section 14 on offences. The First Schedule excludes certain medicinal products from the definition of clinical research material, and the Second Schedule prescribes labelling requirements.
Who Does This Legislation Apply To?
The Regulations apply to persons involved in the lifecycle of CRMs for clinical research—particularly those who manufacture, assemble, import, supply, and otherwise “deal” with CRMs. The definitions in Section 2 include “sponsor” and “subject”, but the operational obligations in Parts 3–5 are directed at those responsible for CRM handling and compliance (for example, manufacturers/importers/suppliers and those managing CRMs at trial sites).
The Regulations also incorporate concepts from the Healthcare Services Act 2020, including “healthcare service licensee” and “approved permanent premises” and “approved conveyance”. This indicates that healthcare service providers and licensed entities may be within the compliance perimeter, especially where CRMs are handled in approved premises or transported using approved conveyances. In practice, sponsors, contract research organisations, trial sites, and pharmaceutical supply chain actors should assess whether their roles trigger obligations under the CRM Regulations.
Why Is This Legislation Important?
The CRM Regulations are important because they balance two competing regulatory needs: (1) enabling clinical research by allowing medicinal products to be used as CRMs under protocols, and (2) maintaining safety, quality, and accountability through enforceable requirements. By providing exemptions from the Medicines Act while imposing CRM-specific duties, the Regulations reduce unnecessary friction for research while preserving core protections for research subjects and the integrity of the research process.
For practitioners, the most significant compliance risks typically arise in three areas: labelling (Second Schedule), record-keeping (Sections 8–11), and safety reporting/recall (Sections 12–13). These are also the areas most likely to be scrutinised during inspections or in the aftermath of adverse events. A failure to keep adequate records can undermine traceability and investigation; inadequate labelling can lead to dosing errors; and delayed or missed adverse reaction notifications can create serious patient safety and regulatory consequences.
From a legal strategy perspective, the Regulations also matter for how parties structure their roles and contracts. Sponsors and trial sites often rely on manufacturers, importers, and suppliers to handle CRMs. The CRM Regulations’ obligations can therefore be used to allocate responsibilities contractually (e.g., who must maintain which records, who must notify the Authority, and who must initiate recall actions). Understanding the statutory duties helps counsel draft compliance clauses that reflect the actual regulatory workflow.
Related Legislation
- Medicines Act (Cap. 176)
- Human Biomedical Research Act 2015 (including the institutional review board framework referenced in Section 2)
- Healthcare Services Act 2020 (definitions and premises/conveyance concepts referenced in Section 2)
- Medicines (Clinical Trials) Regulations 2016 (definition of “regulated clinical trial” cross-reference)
- Health Products (Clinical Trials) Regulations 2016 (definition of “regulated clinical trial” cross-reference)
Source Documents
This article provides an overview of the Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.